Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vext Science's Other Operating Expense for the
three
months ended in Mar. 2026 was €1.22 Mil.
Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was €4.94 Mil.
Vext Science's quarterly Other Operating Expense
declined
from Sep. 2025 (€2.04 Mil) to Dec. 2025 (€-0.46 Mil) but then
increased
from Dec. 2025 (€-0.46 Mil) to Mar. 2026 (€1.22 Mil).
Vext Science's annual Other Operating Expense
increased
from Dec. 2023 (€5.54 Mil) to Dec. 2024 (€5.60 Mil) but then
declined
from Dec. 2024 (€5.60 Mil) to Dec. 2025 (€5.54 Mil).
Vext Science Other Operating Expense Related Terms
Vext Science Other Operating Expense Historical Data
* Premium members only.
The historical data trend for Vext Science's Other Operating Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)
Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.
Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €4.94 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Other Operating Expense of €4.94 Mil mean?
Vext Science (FRA:VV5) has a Other Operating Expense of €4.94 Mil as of Mar. 2026. Other operating expenses that a company records on its income statement. View historical data on Vext Science and its competitors.
Is Vext Science's Other Operating Expense too high?
Vext Science's current Other Operating Expense is €4.94 Mil. Overall, Vext Science has a GF Score™ of 55/100, reflecting its overall financial health beyond just this single metric.
How does Vext Science's Other Operating Expense compare to ZTS?
Vext Science's Other Operating Expense of €4.94 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Drug Manufacturers company?
A good Other Operating Expense depends on the Drug Manufacturers industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Vext Science and its competitors. Vext Science's current Other Operating Expense is €4.94 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vext Science stock overvalued right now?
Vext Science (FRA:VV5) has a current Other Operating Expense of €4.94 Mil. The stock's GF Value™ is €0.96, compared to a current price of €0.16 — trading 83.5% below its estimated fair value. The current Other Operating Expense is €4.94 Mil. Vext Science's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Vext Science (FRA:VV5), the current Other Operating Expense is €4.94 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vext Science (FRA:VV5) Overvalued in 2026?
Based on GuruFocus' analysis, Vext Science stock appears to be undervalued.
The current stock price of €0.16 is trading 83.5% below its estimated GF Value™ of €0.96.
Key valuation signals for FRA:VV5:
Other Operating Expense: €4.94 Mil
GF Value™: €0.96 vs. price of €0.16 (83.5% below fair value)
No single metric tells the full story. See the FRA:VV5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vext Science Inc engages in the full spectrum of the cannabis product lifecycle, from development and manufacturing to distribution. Its brands include Herbal Wellness, Appalachian Pharm, Revibe, Prism, Vapen, and Firebrand. In Arizona and Ohio, the dispensaries operate under the Herbal Wellness Center brand, while in Ohio the cultivation and manufacturing operations are licensed and branded as Appalachian Pharms Cultivation and Appalachian Pharm Processing. The Company operates through a single operating segment engaged in the cultivation, manufacturing, distribution, and sale of cannabis within the United States. All revenues are generated in the United States.
55GF Score
Get the complete analysis for FRA:VV5
Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VV5 has been successfully added to your 
